These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1730278)

  • 1. Combination chemotherapy MOCCA in resistant and relapsing multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1992 Jan; 48(1):37-40. PubMed ID: 1730278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J
    Eur J Haematol; 1990 Feb; 44(2):121-4. PubMed ID: 2180741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. Finnish Leukaemia Group.
    Palva IP; Ala-Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E
    Eur J Haematol; 1993 Aug; 51(2):98-101. PubMed ID: 8370425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved long-term survival in multiple myeloma. Finnish Leukaemia Group.
    Eur J Haematol; 1989 Nov; 43(5):385-8. PubMed ID: 2612611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive combination chemotherapy in multiple myeloma. A multicentre trial. Finnish Leukaemia Group.
    Scand J Haematol; 1985 Aug; 35(2):205-9. PubMed ID: 3901244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.
    Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK
    J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E
    Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO
    Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
    Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
    Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HyperCVAD for VAD-resistant multiple myeloma.
    Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R
    Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group.
    Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E; Kilpi H
    Eur J Haematol; 1989 Oct; 43(4):328-31. PubMed ID: 2583258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
    Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.